Technology | Vascular Access | August 10, 2016

Access Scientific Debuts PowerWand XL Midline Catheter

Catheter designed specifically for component-based, over-wire insertion technique similar to MST

Access Scientific, PowerWand XL midline catheter

August 10, 2016 — Access Scientific introduced the PowerWand XL, a companion to the PowerWand All-in-One, in July. The Powerwand XL is designed specifically for clinicians who prefer to use a component-based, over-wire insertion technique similar to the Modified Seldinger Technique (MST) they currently use.

The XL technique feels similar to the MST, but XL advantages include:

  • Improves clinical outcomes through atraumatic catheter insertion;
  • Designed to reduce risk of deep-vein thrombosis by up to 500 percent. No trimming of catheter necessary;
  • Reduces risk of back leaking. No peel-away sheath;
  • Guidewire extends fully so the catheter does not drag across the intima of the vessel; and
  • Faster and safer because of fewer steps.

As with MST insertions, the XL insertion technique utilizes a 21-gauge safety needle and guidewire to access the vessel. The XL accelerates line placement and makes it safer compared to MST, according to Access Scientific, by eliminating the need for a peelable introducer sheath. Instead, the proprietary PowerWand XL dilator and catheter are inserted directly over the wire and into the bloodstream. This technique eliminates the sheath-related steps in MST that can be associated with such risks as bleeding, back-leaking and vessel damage.

The All-in-One is inserted with the Accelerated Seldinger Technique (AST), which also improves on the MST in speed, number of steps and safety.

Other attributes of the PowerWand XL include:

  • Size: 4Fr and 5Fr;
  • Length: 8 and 10cm;
  • Infection Prevention: Zero BSIs over 12,000 catheter-days;
  • High Flow: Capable of delivering large volumes rapidly, 130-180 ml/min;
  • Power Injectable: 325psi / 8ml per second;
  • Blood Drawable: Allows for blood draws in most patients, 60 – 99 percent; and
  • Patient Satisfaction: Provides patients with one-stick hospitalization.

For more information:

Related Content

News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Overlay Init